Selecta Biosciences Newswire

Selecta Biosciences Newswire

Comprehensive Real-Time News Feed for Selecta Biosciences.

Results 1 - 20 of 58 in Selecta Biosciences

  1. Selecta Biosciences (SELB) Receiving Somewhat Favorable Press Coverage, Accern ReportsRead the original story w/Photo

    Monday Dec 4 | IntersportsWire

    News headlines about Selecta Biosciences have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time.

    Comment?

  2. Achillion Pharmaceuticals (ACHN) & Selecta Biosciences (SELB) Critical ComparisonRead the original story w/Photo

    Wednesday Nov 29 | AmericanBankingNews.com

    Achillion Pharmaceuticals and Selecta Biosciences are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends. Selecta Biosciences has lower revenue, but higher earnings than Achillion Pharmaceuticals.

    Comment?

  3. Selecta Biosciences, Inc. (SELB) Receives Average Rating of "Buy" from AnalystsRead the original story w/Photo

    Monday Nov 27 | AmericanBankingNews.com

    Shares of Selecta Biosciences, Inc. have earned an average recommendation of "Buy" from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company.

    Comment?

  4. Selecta Biosciences: SEL-212 Phase 2 Data Not As Good As Hoped, But The Potential Is Still ThereRead the original story w/Photo

    Tuesday Nov 21 | Seeking Alpha

    ... company's platform can be applied to several potentially lucrative areas, like cancer and gene therapy. Selecta Biosciences ( SELB ) recently reported additional Phase 2 data that were not as compelling as the initial data reported this summer. The ...

    Comment?

  5. Selecta Biosciences: A Contrarian InvestmentRead the original story w/Photo

    Monday Nov 20 | Seeking Alpha

    Additional data from this phase 2 trial will be presented in Q1 2018 . We bought a starter position in Selecta Biosciences last week and added more today.

    Comment?

  6. Selecta Biosciences (SELB) Given Daily News Sentiment Rating of 0.13Read the original story w/Photo

    Sunday Nov 19 | IntersportsWire

    Press coverage about Selecta Biosciences has trended somewhat positive on Sunday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources.

    Comment?

  7. Selecta Biosciences Inc (SELB) President and CEO Werner Cautreels Bought $186,200 of SharesRead the original story w/Photo

    Tuesday Nov 14 | GuruFocus.com

    President and CEO of Selecta Biosciences Inc Werner Cautreels bought 20,000 shares of SELB on 11/13/2017 at an average price of $9.31 a share. The total cost of this purchase was $186,200.

    Comment?

  8. Selecta Biosciences, Inc. (SELB) Insider Acquires $186,200.00 in StockRead the original story w/Photo

    Tuesday Nov 14 | AmericanBankingNews.com

    Selecta Biosciences, Inc. insider Werner Cautreels bought 20,000 shares of the company's stock in a transaction dated Monday, November 13th. The stock was purchased at an average price of $9.31 per share, with a total value of $186,200.00.

    Comment?

  9. Selecta Biosciences to Webcast Investor Conference Presentations This WeekRead the original story

    Monday Nov 13 | Customer Interaction Solutions

    WATERTOWN, Mass., Nov. 13, 2017 -- Selecta Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that CEO and Chairman Werner Cautreels, Ph.D., will be presenting at the following investor conferences: Among the presentation topics will be Selecta's ongoing Phase 2 trial of SEL-212 for chronic severe gout. Live and archived webcasts of these presentations will be available on the Investors & Media section of the Selecta website at www.selectabio.com .

    Comment?

  10. Selecta Biosciences, Inc. (SELB) Upgraded to "Buy" by Zacks Investment ResearchRead the original story w/Photo

    Saturday Nov 11 | AmericanBankingNews.com

    ... would indicate a potential upside of 10.74% from the stock's current price. According to Zacks, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene ...

    Comment?

  11. Selecta Biosciences, Inc. (Selb) Downgraded to "Neutral" at Ubs AgRead the original story w/Photo

    Nov 9, 2017 | AmericanBankingNews.com

    Other equities research analysts have also issued research reports about the stock. Canaccord Genuity set a $25.00 price objective on shares of Selecta Biosciences and gave the company a "buy" rating in a research note on Wednesday, July 26th.

    Comment?

  12. Selecta Biosciences to Report Third Quarter 2017 Financial Results...Read the original story

    Oct 31, 2017 | Customer Interaction Solutions

    Selecta Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that it plans to issue its third quarter 2017 financial results and report updated patient data from its ongoing Phase 2 trial of SEL-212 before the market's open on Tuesday, November 7, 2017. At 8:30 a.m. ET that day, Selecta will host a conference call to discuss these results and provide a corporate update.

    Comment?

  13. Selecta Biosciences, Inc. (SELB) Price Target Raised to $30.00 at Canaccord GenuityRead the original story w/Photo

    Oct 13, 2017 | IntersportsWire

    ... the stock. A number of other brokerages have also weighed in on SELB. Zacks Investment Research raised Selecta Biosciences from a sell rating to a hold rating in a report on Thursday. ValuEngine raised Selecta Biosciences from a sell rating to a ...

    Comment?

  14. Selecta Biosciences, Inc. (SELB) PT Raised to $30.00Read the original story w/Photo

    Oct 12, 2017 | AmericanBankingNews.com

    ... analysts also recently issued research reports about the company. Zacks Investment Research upgraded Selecta Biosciences from a "sell" rating to a "hold" rating in a research note on Wednesday, July 12th. ValuEngine upgraded Selecta Biosciences from ...

    Comment?

  15. Selecta Biosciences Announces Upcoming Clinical and Scientific PresentationsRead the original story

    Oct 5, 2017 | Customer Interaction Solutions

    WATERTOWN, Mass., Oct. 05, 2017 -- Selecta Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced the following upcoming clinical presentations: Development of a Novel Adeno-Associated Viral Vector in Combination with Tolerogenic Nanoparticles for the Treatment of Ornithine Transcarbamylase Deficiency Design and Early Clinical Development of SEL-212, a Non-Immunogenic Pegylated Uricase for the Treatment of Chronic Severe Gout Clinical Development of SEL-212: Use of Tolerogenic Nanoparticles to Mitigate Immunogenicity Against an Enzyme Therapy to Treat Severe Gout Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase with SVP-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation ... (more)

    Comment?

  16. ValuEngine Downgrades Selecta Biosciences, Inc. (SELB) to SellRead the original story w/Photo

    Sep 28, 2017 | Daily Political

    SELB has been the subject of several other reports. Zacks Investment Research upgraded shares of Selecta Biosciences from a "sell" rating to a "hold" rating in a research report on Wednesday, July 12th.

    Comment?

  17. Gout Therapeutics Market - Advanced Technologies & Growth Opportunities in Global Industry 2025Read the original story

    Sep 15, 2017 | SBWire

    ... Sciences, Ironwood Pharmaceuticals, Incyte, KaloBios Pharmaceuticals, Morphotek, Sanofi, Santarus, and Selecta Biosciences are some of the other key companies in the global gout therapeutics market. About TMR Research TMR Research is a premier ...

    Comment?

  18. Selecta Biosciences (SELB) Receiving Somewhat Favorable Press Coverage, Report ShowsRead the original story w/Photo

    Sep 2, 2017 | Daily Political

    Media stories about Selecta Biosciences have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time.

    Comment?

  19. Selecta Biosciences (SELB) Given Daily Media Impact Score of 0.09Read the original story w/Photo

    Aug 27, 2017 | IntersportsWire

    Press coverage about Selecta Biosciences has trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time.

    Comment?

  20. Selecta Biosciences, Inc. (SELB) PT Set at $25.00 by Canaccord GenuityRead the original story w/Photo

    Aug 15, 2017 | IntersportsWire

    ... on SELB. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price target on shares of Selecta Biosciences in a research report on Tuesday, March 28th. UBS AG reiterated a "buy" rating and issued a $26.00 price target on shares of ...

    Comment?